[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2012119787A1 - Amatoxin-conjugates with improved linkages - Google Patents

Amatoxin-conjugates with improved linkages Download PDF

Info

Publication number
WO2012119787A1
WO2012119787A1 PCT/EP2012/001072 EP2012001072W WO2012119787A1 WO 2012119787 A1 WO2012119787 A1 WO 2012119787A1 EP 2012001072 W EP2012001072 W EP 2012001072W WO 2012119787 A1 WO2012119787 A1 WO 2012119787A1
Authority
WO
WIPO (PCT)
Prior art keywords
amatoxin
cancer
target
linker
group
Prior art date
Application number
PCT/EP2012/001072
Other languages
French (fr)
Inventor
Werner Simon
Christian Lutz
Christoph Müller
Jan Anderl
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2013145314/04A priority Critical patent/RU2575854C2/en
Priority to BR112013023015-0A priority patent/BR112013023015B1/en
Priority to ES12708251.9T priority patent/ES2532855T3/en
Priority to CA2829421A priority patent/CA2829421C/en
Priority to CN201280012636.7A priority patent/CN103442736B/en
Priority to EP12708251.9A priority patent/EP2683409B1/en
Priority to SG2013068135A priority patent/SG193392A1/en
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Priority to US14/004,183 priority patent/US20140294865A1/en
Priority to JP2013557012A priority patent/JP6105492B2/en
Priority to KR1020137026713A priority patent/KR101988005B1/en
Priority to NZ614548A priority patent/NZ614548B2/en
Priority to MX2013010286A priority patent/MX344009B/en
Priority to AU2012224848A priority patent/AU2012224848B2/en
Priority to UAA201311873A priority patent/UA110370C2/en
Publication of WO2012119787A1 publication Critical patent/WO2012119787A1/en
Priority to IL228191A priority patent/IL228191A/en
Priority to ZA2013/07526A priority patent/ZA201307526B/en
Priority to HK14105777.2A priority patent/HK1192839A1/en
Priority to US15/728,170 priority patent/US20180185509A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to tumour therapy.
  • the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer.
  • a target-binding moiety e.g. an antibody
  • the invention relates to pharmaceutical compositions comprising such conjugates.
  • Patent application EP 1 859 811 A1 (published November 28, 2007) described conjugates, in which the ⁇ C-atom of amatoxin amino acid 1 of ⁇ -amanitin was directly coupled, i.e. without a linker structure, to albumin or to monoclonal antibody HEA125, OKT3, or PA-1. Furthermore, the inhibitory effect of these conjugates on the proliferation of breast cancer cells (MCF-7), Burkitt's lymphoma cells (Raji), and T- lymphoma cells (Jurkat) was shown.
  • MCF-7 breast cancer cells
  • Raj Burkitt's lymphoma cells
  • Jurkat T- lymphoma cells
  • linkers including linkers comprising elements such as amide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moieties and the like, but no such constructs were actually shown, and no more details, such as attachment sites on the amatoxins, were provided.
  • Patent applications WO 2010/115629 and WO 2010/1 15630 (both published October 14, 2010) describe conjugates, where antibodies, such as anti- EpCAM antibodies such as humanized antibody huHEA125, are coupled to amatoxins via (i) the ⁇ C-atom of amatoxin amino acid 1 , (ii) the 6' C-atom of amatoxin amino acid 4, or (iii) via the ⁇ C-atom of amatoxin amino acid 3, in each case either directly or via a linker between the antibody and the amatoxins.
  • the suggested linkers comprise elements such as amide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moieties and the like.
  • the inhibitory effects of these conjugates on the proliferation of breast cancer cells (cell line MCF-7), pancreatic carcinoma (cell line Capan-1), colon cancer (cell line Colo205), and cholangiocarcinoma (cell line OZ) were shown.
  • amatoxins are relatively non-toxic when coupled to large biomolecule carriers, such as antibody molecules, and that they exert their cytotoxic activity only after the biomolecule carrier is cleaved off.
  • biomolecule carriers such as antibody molecules
  • amatoxin conjugates for targeted tumour therapy remain highly stable after administration in plasma, and that the release of the amatoxin occurs after internalization in the target cells.
  • minor improvements of the conjugate stability may have drastic consequences for the therapeutic window and the safety of the amatoxin conjugates for therapeutic approaches.
  • the present invention is based on the unexpected observation that targeting moieties can be attached to amatoxins via linkers at additional attachment sites on tryptophan amino acid 4, namely positions 1'-N without interference with the interaction of such amatoxins with their target, the DNA-dependent RNA polymerase II of mammalian cells.
  • the present invention relates to a conjugate comprising a target- binding moiety linked via a linker L to an amatoxin, or an analogue of an amatoxin, wherein the linker L is connected to the amatoxin via the 1'-N atom of amino acid 4.
  • the present invention relates to an amatoxin conjugate of Formula I
  • R1 H or OH
  • R2 H or OH
  • R3 NH 2 or OH
  • R4 OH or OC 1-6 -alkyl
  • R5 L-T; wherein L is a linker; and T is a target binding moiety.
  • the present invention relates to a pharmaceutical composition comprising the conjugate according to the present invention.
  • the present invention relates to a method for synthesizing a conjugate of the present invention, comprising the step of reacting an amatoxin-conjugation molecule of the present invention with a target-binding moiety comprising a nucleophilic group, particularly a primary amine.
  • Fig. 1 shows the structural formulae of different amatoxins.
  • the numbers in bold type (1 to 8) designate the standard numbering of the eight amino acids forming the amatoxin.
  • the standard designations of the atoms in amino acids 1 , 3 and 4 are also shown (Greek letters a to ⁇ , Greek letters a to ⁇ , and numbers from 1 ' to 7', respectively).
  • FIG. 2 shows the cytotoxic activity of Her-DSC-30.0378 [2.8] on a HER2- positive tumor cell line in vitro in a BrdU assay after incubation for 72 h.
  • the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (lUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH- 4010 Basel, Switzerland).
  • the present invention relates to a conjugate comprising a target- binding moiety linked via a linker L to an amatoxin, or an analogue of an amatoxin, wherein the linker L is connected to the amatoxin via the 1 '-N atom of amino acid 4.
  • conjugate refers to a molecule comprising at least two different molecules linked by a covalent bond.
  • target-binding moiety refers to any molecule or part of a molecule that can specifically bind to a target molecule or target epitope.
  • Preferred target-binding moieties in the context of the present application are (i) antibodies or antigen-binding fragments thereof; (ii) antibody-like proteins; and (iii) nucleic acid aptamers.
  • “Target-binding moieties” suitable for use in the present invention typically have a molecular mass of 40 000 Da (40 kDa) or more.
  • a first compound e.g. an antibody
  • a second compound e.g. an antigen, such as a target protein
  • K D dissociation constant K D to said second compound of 100 ⁇ or less, preferably 50 ⁇ or less, preferably 30 ⁇ or less, preferably 20 ⁇ or less, preferably 10 ⁇ or less, preferably 5 ⁇ or less, more preferably 1 ⁇ or less, more preferably 900 nM or less, more preferably 800 nM or less, more preferably 700 nM or less, more preferably 600 nM or less, more preferably 500 nM or less, more preferably 400 nM or less, more preferably 300 nM or less, more preferably 200 nM or less, even more preferably 100 nM or less, even more preferably 90 nM or less, even more preferably 80 nM or less, even more preferably 70 nM or less, even more preferably 60 n
  • target molecule In the context of the present application the terms "target molecule” and
  • target epitope refers to an antigen and an epitope of an antigen, respectively, that is specifically bound by a target-binding moiety.
  • the target molecule is a tumour-associated antigen, in particular an antigen or an epitope which is present on the surface of one or more tumour cell types in an increased concentration and/or in a different steric configuration as compared to the surface of non-tumour cells
  • said antigen or epitope is present on the surface of one or more tumour cell types, but not on the surface of non-tumour cells.
  • the target- binding moiety specifically binds to an epitope of HER-2/neu or epithelial cell adhesion molecule (EpCAM).
  • said antigen or epitope is preferentially expressed on cells involved in autoimmune diseases.
  • the target-binding moiety specifically binds to an epitope of the IL-6 receptor (IL-6R).
  • IL-6R IL-6 receptor
  • antibody or antigen binding fragment thereof refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain an antigen-binding site that immunospecifically binds an antigen. Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to a target molecule, e.g. to the target protein Her-2/neu or EpCAM.
  • the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2) or subclass of immunoglobulin molecule.
  • Antibodies and antigen-binding fragments thereof suitable for use in the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, human, humanized (in particular CDR-grafted), deimmunized, or chimeric antibodies, single chain antibodies (e.g.
  • scFv fragments
  • F(ab') 2 fragments fragments produced by a Fab expression library
  • diabodies or tetrabodies Holliger P. et al., 1993
  • nanobodies anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope- binding fragments of any of the above.
  • the antigen-binding fragments are human antigen- binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide- linked Fvs (dsFv) and fragments comprising either a VL or VH domain.
  • Antigen-binding antibody fragments, including single-chain antibodies may comprise the variable domain(s) alone or in combination with the entirety or a portion of the following: hinge region, CL, CH1 , CH2, and CH3 domains.
  • antigen- binding fragments also comprising any combination of variable domain(s) with a hinge region, CL, CH1 , CH2, and CH3 domains.
  • Antibodies usable in the invention may be from any animal origin including birds and mammals.
  • the antibodies are from human, rodent (e.g. mouse, rat, guinea pig, or rabbit), chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog origin. It is particularly preferred that the antibodies are of human or murine origin.
  • "human antibodies” include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described for example in U.S. Patent No. 5,939,598 by Kucherlapati & Jakobovits.
  • antibody-like protein refers to a protein that has been engineered (e.g. by mutagenesis of loops) to specifically bind to a target molecule.
  • an antibody-like protein comprises at least one variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the antibody-like protein to levels comparable to that of an antibody.
  • the length of the variable peptide loop typically consists of 10 to 20 amino acids.
  • the scaffold protein may be any protein having good solubility properties.
  • the scaffold protein is a small globular protein.
  • Antibody-like proteins include without limitation affibodies, anticalins, and designed ankyrin repeat proteins (for review see: Binz et al. 2005).
  • Antibody-like proteins can be derived from large libraries of mutants, e.g. be panned from large phage display libraries and can be isolated in analogy to regular antibodies. Also, antibody-like binding proteins can be obtained by combinatorial mutagenesis of surface-exposed residues in globular proteins.
  • nucleic acid aptamer refers to a nucleic acid molecule that has been engineered through repeated rounds of in vitro selection or SELEX (systematic evolution of ligands by exponential enrichment) to bind to a target molecule (for a review see: Brody and Gold, 2000).
  • the nucleic acid aptamer may be a DNA or RNA molecule.
  • the aptamers may contain modifications, e.g. modified nucleotides such as 2'-fluorine- substituted pyrimidines.
  • an "analogue" of a compound is structurally related but not identical to the compound and exhibits at least one activity of the compound.
  • the compound to which the analogue is compared is known as the "parent” compound.
  • the afore-mentioned activities include, without limitation: binding activity to another compound; inhibitory activity, e.g. enzyme inhibitory activity; toxic effects; activating activity, e.g. enzyme-activating activity. It is not required that the analogue exhibits such an activity to the same extent as the parent compound.
  • a compound is regarded as an analogue within the context of the present application, if it exhibits the relevant activity to a degree of at least 1 % (more preferably at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, and more preferably at least 50%) of the activity of the parent compound.
  • an "analogue of an amatoxin" refers to a compound that is structurally related to any one of a-amanitin, ⁇ -amanitin, y-amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, and amanullinic acid as shown in Fig.
  • RNA polymerase II that exhibits at least 1 % (more preferably at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, and more preferably at least 50%) of the inhibitory activity against mammalian RNA polymerase II as compared to at least one of a-amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, and amanullinic acid.
  • an "analogue of an amatoxin" suitable for use in the present invention may even exhibit a greater inhibitory activity against mammalian RNA polymerase II than any one of a-amanitin, ⁇ -amanitin, y-amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, or amanullinic acid.
  • the inhibitory activity might be measured by determining the concentration at which 50% inhibition occurs (IC 50 value).
  • the inhibitory activity against mammalian RNA polymerase II can be determined indirectly by measuring the inhibitory activity on cell proliferation. A suitable assay for measuring inhibition of cell proliferation is described in the examples.
  • a "semisynthetic analogue” refers to an analogue that has been obtained by chemical synthesis using compounds from natural sources (e.g. plant materials, bacterial cultures, or cell cultures) as starting material. Typically, a “semisynthetic analogue” of the present invention has been synthesized starting from a compound isolated from a mushroom of the Amanita family. In contrast, a “synthetic analogue” refers to an analogue synthesized by so-called total synthesis from small (typically petrochemical) building blocks. Usually, this total synthesis is carried out without the aid of biological processes.
  • an "aptamer conjugate” refers to a target-binding moiety toxin conjugate in which the target-binding moiety is a nucleic acid aptamer according to above alternative (iii).
  • a "linker” in the context of the present invention refers to a molecule that is connecting two components, each being attached to one end of the linker, and which increases the distance between two components and alleviates steric interference between these components, such as in the present case between the target-binding moiety and the amatoxin.
  • a linker In the absence of a linker, a direct linkage of amatoxin to the target-binding moiety may decrease the ability of the amatoxin to interact with RNA polymerase II.
  • a linker has a continuous chains of between 1 and 30 atoms (e.g.
  • the term "between” is used so that the borders mentioned are included) in its backbone, i.e. the length of the linker is defined as the shortest connection as measured by the number of atoms or bonds between the amatoxin moiety and the target-binding moiety, wherein one side of the linker backbone has been reacted with the amatoxin and, the other side with a target-binding moiety.
  • a linker preferably is an Ci -2 o-alkylene, d-20-heteroalkylene, C 2 .2 0 -alkenylene, C 2- 2o- heteroalkenylene, C 2 -2o-alkynylene, C 2- 2o-heteroalkynylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or a heteroaralkylene group, optionally substituted.
  • the linker may contain one or more structural elements such as carboxamide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moieties and the like.
  • the linker may also contain combinations of two or more of these structural elements. Each one of these structural elements may be present in the linker more than once, e.g. twice, three times, four times, five times, or six times. In some embodiments the linker may comprise a disulfide bond. It is understood that the linker has to be attached either in a single step or in two or more subsequent steps to the amatoxin and the target-binding moiety.
  • the linker to be will carry two groups, preferably at a proximal and distal end, which can (i) form a covalent bond to a group present in one of the components to be linked, preferably an activated group on an amatoxin or the target binding-peptide or (ii) which is or can be activated to form a covalent bond with a group on an amatoxin.
  • chemical groups are at the distal and proximal end of the linker, which are the result of such a coupling reaction, e.g. an ester, an ether, a urethane, a peptide bond etc.
  • amatoxin includes all cyclic peptides composed of 8 amino acids as isolated from the genus Amanita and described in Wieland, T. and Faulstich H. (Wieland T, Faulstich H., CRC Crit Rev Biochem.
  • amatoxins are defined as peptides or depsipeptides that inhibit mammalian RNA polymerase II.
  • Preferred amatoxins are those with a functional group (e.g. a carboxylic group, an amino group, a hydroxy group, a thiol or a thiol- capturing group) that can be reacted with linker molecules or target-binding moieties as defined above.
  • Amatoxins which are particularly suitable for the conjugates of the present invention are ct-amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, and amanullinic acid as shown in Fig. 1 as well as salts, chemical derivatives, semisynthetic analogues, and synthetic analogues thereof.
  • Particularly preferred amatoxins for use in the present invention are a-amanitin, ⁇ - amanitin, and amaninamide.
  • a “chemical derivative” (or short: a “derivative”) of a compound refers to a species having a chemical structure that is similar to the compound, yet containing at least one chemical group not present in the compound and/or deficient of at least one chemical group that is present in the compound.
  • the compound to which the derivative is compared is known as the "parent” compound.
  • a “derivative” may be produced from the parent compound in one or more chemical reaction steps.
  • the amatoxin is selected from a-amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, or amanullinic acid, or from salts or analogues thereof.
  • the present invention relates to an amatoxin conjugate of
  • R1 H or OH
  • R2 H or OH
  • R3 NH 2 or OH
  • R4 OH or OCi-e-alkyl
  • R5 L-T; wherein L is a linker; and T is a target binding moiety.
  • R4 is O-Me.
  • the linker is connected to the target-binding moiety via a urea moiety.
  • the term "connected to the target- binding moiety via a urea moiety” refers to a connection between the linker and the target-binding moiety, where the target-binding moiety is directly attached to the linker via an -NH-C(O)-NH- group.
  • the target-binding moiety is connected to the linker L via an amino group present in the target-binding moiety, wherein said amino group forms part of said urea moiety.
  • the linker has a length of between 1 and 8 atoms, particularly between 1 and 6, more particularly between 1 and 4, and most particularly between 2 and 4 atoms.
  • an ethylene linker has a linker length of 2 atoms, a propylene linker of 3 atoms, and a butylene linker of 4 atoms
  • the linker L comprises one or more groups, particularly one, two or three groups, selected from the list of: alkylene, alkenylene, alkynylene, cycloalkylene, heteroalkylene, heteroalkenylene, heteroalkynylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, and a heteroaralkylene group, wherein each group may optionally be independently substituted.
  • alkylene refers to a bivalent straight chain saturated hydrocarbon groups having from 1 to 20 carbon atoms, including groups having from 1 to 10 carbon atoms. In certain embodiments, alkylene groups may be lower alkylene groups.
  • lower alkylene refers to alkylene groups having from 1 to 6 carbon atoms, and in certain embodiments from 1 to 5 or 1 to 4 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2-CH2-), n-propylene, n-butylene, n-pentylene, and n-hexylene.
  • alkenylene refers to bivalent straight chain groups having 2 to 20 carbon atoms, wherein at least one of the carbon-carbon bonds is a double bond, while other bonds may be single bonds or further double bonds.
  • alkynylene herein refers to groups having 2 to 20 carbon atoms, wherein at least one of the carbon- carbon bonds is a triple bond, while other bonds may be single, double or further triple bonds.
  • alkynylene groups include ethynylene, 1-propynylene, 2-propynylene, and so forth.
  • cycloalkylene is intended to refer to a bivalent ring being part of any stable monocyclic or polycyclic system, where such ring has between 3 and 12 carbon atoms, but no heteroatom, and where such ring is fully saturated
  • cycloalkenylene is intended to refer to a bivalent ring being part of any stable monocyclic or polycyclic system, where such ring has between 3 and 12 carbon atoms, but no heteroatom, and where such ring is at least partially unsaturated (but excluding any arylene ring).
  • cycloalkylenes include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and cycloheptylene.
  • cycloalkenylenes include, but are not limited to, cyclopentenylene and cyclohexenylene.
  • heterocycloalkylene and
  • heterocycloalkenylene are intended to refer to a bivalent ring being part of any stable monocyclic or polycyclic ring system, where such ring has between 3 and about 12 atoms, and where such ring consists of carbon atoms and at least one heteroatom, particularly at least one heteroatom independently selected from the group consisting of N, O and S, with heterocycloalkylene referring to such a ring that is fully saturated, and heterocycloalkenylene referring to a ring that is at least partially unsaturated (but excluding any arylene or heteroarylene ring).
  • arylene is intended to mean a bivalent ring or ring system being part of any stable monocyclic or polycyclic system, where such ring or ring system has between 3 and 20 carbon atoms, but has no heteroatom, which ring or ring system consists of an aromatic moiety as defined by the "4n+2" ⁇ electron rule, including phenylene.
  • heteroarylene refers to a bivalent ring or ring system being part of any stable mono- or polycyclic system, where such ring or ring system has between 3 and 20 atoms, which ring or ring system consists of an aromatic moiety as defined by the "4n+2" ⁇ electron rule and contains carbon atoms and one or more nitrogen, sulfur, and/or oxygen heteroatoms.
  • substituted is intended to indicate that one or more hydrogens present in the backbone of a linker is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency, or that of the appropriate atom of the group that is substituted, is not exceeded, and that the substitution results in a stable compound.
  • optionally substituted is intended to mean that the linker is either unsubstituted or substituted, as defined herein, with one or more substituents, as defined herein. When a substituent is a keto (or oxo, i.e.
  • substituents include, for example, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, aroyl, heteroaroyl, carboxyl, alkoxy, aryloxy, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, halogen, (thio)ester, cyano, phosphoryl, amino, imino, (thio)amido, sulfhydryl, alkylthio, acylthio, sulfonyl, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, nitro, azido, haloal
  • n is 1-4 and R is independently selected from hydrogen, -alkyl, - alkenyl, -alkynyl
  • n is 2 and n is 1 , or m is 3 and n is 2.
  • the linker comprises 2 or 3 unsubstituted alkylene groups, and 1 or 2, respectively, disulfide, ether, thioether, amine, ester, carboxamide, urethane or urea moieties linking the unsubstituted alkylene groups.
  • the target-binding moiety specifically binds to an epitope that is present on a tumour cell.
  • the target-binding moiety specifically binds to an epitope of Her-2/neu or epithelial cell adhesion molecule (EpCAM).
  • EpCAM epithelial cell adhesion molecule
  • the target-binding moiety is selected from the group consisting of: antibody or antigen-binding fragment thereof; antibody-like protein; and nucleic acid aptamer.
  • the antibody or the antigen-binding fragment thereof is selected from a diabody, a tetrabody, a nanobody, a chimeric antibody, a deimmunized antibody, a humanized antibody or a human antibody.
  • the antigen binding fragment is selected from the group consisting of Fab, F(ab') 2 , Fd, Fv, single-chain Fv, and disulfide-linked Fvs (dsFv).
  • the antibody is herceptin or HEA125, or an antibody fragment comprising the antigen binding fragment of herceptin or ⁇ 125.
  • more than one amatoxin molecule is coupled to one target-binding moiety.
  • An increase of the number of amatoxins per conjugate will also increase the toxicity.
  • the ratio of target- binding moiety to amatoxin is between 1 target-binding moiety to between 2 and 15 amatoxin molecules, particularly 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15.
  • the dimer is considered as one target-binding moiety.
  • the conjugate is for use as a medicament.
  • the conjugate is for use in the treatment of cancer in a patient, wherein the cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma.
  • the cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma.
  • the present invention relates to a method for the treatment of cancer in a patient, wherein the cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma, comprising the step of administering a conjugate of the present invention to a patient in need thereof.
  • a "patient” means any mammal or bird who may benefit from a treatment with the target-binding moiety toxin conjugates described herein.
  • a “patient” is selected from the group consisting of laboratory animals (e.g. mouse or rat), domestic animals (including e.g. guinea pig, rabbit, chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog), or primates including human beings. It is particularly preferred that the "patient” is a human being.
  • treat means accomplishing one or more of the following: (a) reducing the severity of the disorder; (b) limiting or preventing development of symptoms characteristic of the disorder(s) being treated; (c) inhibiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting or preventing recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder(s).
  • the treatment may comprise administering a conjugate or a pharmaceutical composition according to the present invention to a patient, wherein "administering" includes in vivo administration, as well as administration directly to tissue ex vivo, such as vein grafts.
  • a therapeutically effective amount of the conjugate of the present invention is used.
  • a “therapeutically effective amount” is an amount of a therapeutic agent sufficient to achieve the intended purpose.
  • the effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration.
  • the effective amount in each individual case may be determined empirically by a skilled artisan according to established methods in the art.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the conjugate according to the present invention, further comprising one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • the pharmaceutical composition is used in the form of a systemically administered medicament.
  • parenterals which comprise among others injectables and infusions.
  • injectables are formulated either in the form of ampoules or as so called ready-for-use injectables, e.g. ready-to-use syringes or single-use syringes and aside from this in puncturable flasks for multiple withdrawal.
  • the administration of injectables can be in the form of subcutaneous (s.c), intramuscular (i.m.), intravenous (i.v.) or intracutaneous (i.e.) application.
  • Injectable formulations can further be produced as concentrates, which can be dissolved or dispersed with aqueous isotonic diluents.
  • the infusion can also be prepared in form of isotonic solutions, fatty emulsions, liposomal formulations and micro- emulsions. Similar to injectables, infusion formulations can also be prepared in the form of concentrates for dilution. Injectable formulations can also be applied in the form of permanent infusions both in in-patient and ambulant therapy, e.g. by way of mini-pumps.
  • parenteral drug formulations for example, albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances to influence the adsorption of the target-binding moiety toxin conjugates of the invention to proteins or polymers or they can also be added with the aim to reduce the adsorption of the target-binding moiety toxin conjugates of the invention to materials like injection instruments or packaging-materials, for example, plastic or glass.
  • parenteral drug formulations for example, albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances to influence the adsorption of the target-binding moiety toxin conjugates of the invention to proteins or polymers or they can also be added with the aim to reduce the adsorption of the target-binding moiety toxin conjugates of the invention to materials like injection instruments or packaging-materials, for example, plastic or glass.
  • target-binding moiety toxin conjugates of the invention can be bound to microcarriers or nanoparticles in parenterals like, for example, to finely dispersed particles based on poly(meth)acrylates, polylactates, polyglycolates, polyamino acids or polyether urethanes.
  • Parenteral formulations can also be modified as depot preparations, e.g.
  • the target-binding moiety toxin conjugates of the invention are introduced in finely dispersed, dispersed and suspended form, respectively, or as a suspension of crystals in the medicament or based on the "single unit principle” if the target-binding moiety toxin conjugate of the invention is enclosed in a formulation, e.g. in a tablet or a rod which is subsequently implanted.
  • a formulation e.g. in a tablet or a rod which is subsequently implanted.
  • implants or depot medicaments in single unit and multiple unit formulations often consist of so called biodegradable polymers like e.g. polyesters of lactic acid and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.
  • Adjuvants and carriers added during the production of the pharmaceutical compositions of the present invention formulated as parenterals are preferably aqua sterilisata (sterilized water), pH value influencing substances like, e.g. organic or inorganic acids or bases as well as salts thereof, buffering substances for adjusting pH values, substances for isotonization like e.g. sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides and surfactants, respectively, and emulsifiers like, e.g. partial esters of fatty acids of polyoxyethylene sorbitans (for example, Tween®) or, e.g.
  • fatty acid esters of polyoxyethylenes for example, Cremophor®
  • fatty oils like, e.g. peanut oil, soybean oil or castor oil
  • synthetic esters of fatty acids like, e.g. ethyl oleate, isopropyl myristate and neutral oil (for example, Miglyol®) as well as polymeric adjuvants like, e.g. gelatine, dextran, polyvinylpyrrolidone, additives which increase the solubility of organic solvents like, e.g. propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex forming substances like, e.g.
  • citrate and urea preservatives like, e.g. benzoic acid hydroxypropyl ester and methyl ester, benzyl alcohol, antioxidants like e.g. sodium sulfite and stabilizers like e.g. EDTA.
  • preservatives like, e.g. benzoic acid hydroxypropyl ester and methyl ester, benzyl alcohol, antioxidants like e.g. sodium sulfite and stabilizers like e.g. EDTA.
  • compositions of the present invention when formulating the pharmaceutical compositions of the present invention as suspensions in a preferred embodiment thickening agents to prevent the setting of the target-binding moiety toxin conjugates of the invention or, tensides and polyelectrolytes to assure the resuspendability of sediments and/or complex forming agents like, for example, EDTA are added. It is also possible to achieve complexes of the active ingredient with various polymers. Examples of such polymers are polyethylene glycol, polystyrol, carboxymethyl cellulose, Pluronics® or polyethylene glycol sorbit fatty acid ester.
  • the target-binding moiety toxin conjugates of the invention can also be incorporated in liquid formulations in the form of inclusion compounds e.g.
  • dispersing agents can be added as further adjuvants.
  • scaffolding agents like mannite, dextran, saccharose, human albumin, lactose, PVP or varieties of gelatine can be used.
  • the present invention is directed to a method of treating pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, or malignant lymphoma in a patient in need thereof, comprising administering to the patient an effective amount of a conjugate or pharmaceutical composition of the present invention.
  • the present invention relates to an amatoxin-conjugation molecule comprising a leaving group X attached to a linker L connected to an amatoxin, or an analogue of an amatoxin, wherein the linker L is connected to the amatoxin via the T-N atom of amino acid 4.
  • the present invention relates to an amatoxin-conjugation molecule of Formula I
  • R1 H or OH
  • R2 H or OH
  • R3 NH 2 or OH
  • R4 OH or OC 1-6 -alkyl
  • R5 L-X; wherein L is a linker; and X is a leaving group that can be replaced by a nucleophilic group of a target-binding moiety.
  • the nucleophilic group is a primary amine.
  • amatoxin-conjugation molecule of Formula 1 [0082] In a particular embodiment, the amatoxin-conjugation molecule of Formula
  • R4 is O-Me.
  • the linker has a length of between 1 and 8 atoms, particularly between 1 and 6, more particularly between 1 and 4, and most particularly between 2 and 4 atoms.
  • the linker L is an alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or a heteroaralkylene group, optionally substituted.
  • the linker L comprises a moiety selected from one of the following moieties: a disulfide, an ether, an amine, an ester, a carboxamide, a urethane, and a urea moiety.
  • the functional group X is selected from: 'butyloxy, succinimidyloxy, 1-0-succinimidyloxy-3-sulfonate (Sulfo-NHS), 0-(4-nitrophenyloxy), O- (3-nitrophenyloxy), 0-(2,4-dinitrophenyloxy), 0-(2,4-dichloro-6-nitrophenyloxy), pentafluorophenyloxy, pentachlorophenyloxy, 0-(2,4,5-trichlorophenyloxy), 0-(3,4- dihydro-3-hydroxy-4-oxo-1 ,2,3-benzotriazine-3-yl), 0-(endo-1 -hydroxy-5-norbornene-2,3- dicarboximide-1-yl), 1-phthalimidoyloxy, 1-benzotriazolyloxy, 1 -(7-aza-benzotriazolyl)oxy, and N-imidazolyl
  • the present invention relates to a method for synthesizing an amatoxin conjugate of the present invention, comprising the step of reacting an amatoxin-conjugation molecule of the present invention with a target-binding moiety comprising a nucleophilic group, particularly a primary amine.
  • the present invention relates to a method for synthesizing an amatoxin-conjugation molecule of the present invention, comprising the step of (i) reacting an amatoxin with a linker molecule Y-L-X, wherein Y is a moiety that can react with 1'-N atom of amino acid 4 of the amatoxin, and wherein X is a is a leaving group that can be replaced by a nucleophilic group of a target-binding moiety, particularly by a primary amine.
  • the present invention relates to a method for synthesizing an amatoxin-conjugation molecule of the present invention, comprising the step of (i) reacting an amatoxin with a linker molecule Y-L-Z, wherein Y is a moiety that can react with 1'-N atom of amino acid 4 of the amatoxin, and wherein Z is a moiety, which can be converted into a leaving group X, that can be replaced by a nucleophilic group of a target-binding moiety, particularly by a primary amine.
  • the amatoxin is reacted with a linker molecule Y-
  • the amatoxin is treated with Y-L-X, or Y-L-Z, respectively, in the presence of a base, particularly KO'Bu, LiOH or NaH, in a solvent, particularly in a polar, aprotic solvent such as DMF, D SO, or NMP.
  • a base particularly KO'Bu, LiOH or NaH
  • a solvent particularly in a polar, aprotic solvent such as DMF, D SO, or NMP.
  • the protected primary amino is first deprotected and then activated by a carbonic acid derivative, such as dihydroxysuccinimido carbonate (DSC).
  • DSC dihydroxysuccinimido carbonate
  • Solvent B 10% water: 90% methanol, 0.05% trifluoroacetic acid. Gradient: 0-5 min 100% A; 5-20 min 0% A; 20- 25 min 0% A; 25-27 min 100% A; 27-35 min 100% A; the fraction with the retention time of 14.9-15.5 min was collected and the solvents evaporated and freeze dried to a powder.
  • Solvent B 10% water: 90% methanol, 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A; the fraction with the retention time of 21.0 min was collected and the solvents evaporated in vacuum.
  • Solvent A 100% water.
  • Solvent B 100% methanol.
  • the fraction with the retention time of 16.5 min was collected and the solvents evaporated.
  • HDP 30.0636 was obtained as a white powder. MS: 1 118.5 (M+H + ). The product was used for the next step.
  • HDP 30.0636 was dissolved in 400 ⁇ trifluoroacetic acid and stirred for 5 min at room temperature.
  • the reaction mixture was diluted with 1000 ⁇ toluene and evaporated to dryness at ambient temperature.
  • Solvent A 95% water: 5% methanol 0.05% trifluoroacetic acid.
  • Solvent B 10% water: 90% methanol 0.05% trifluoroacetic acid.
  • Gradient 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 18.0 min was collected and the solvents evaporated in vacuum.
  • HDP 30.0677 was obtained as a white solid. MS: 1047.4 (M+H + ). The residue was used for the next step.
  • HDP 30.0680 was dissolved in 500 ⁇ trifluoroacetic acid and stirred for 10 min at room temperature and evaporated to dryness at ambient temperature. The residue was co-evaporated two times with 4 ml toluene.
  • Solvent A 95% water: 5% methanol 0.05% trifluoroacetic acid.
  • Solvent B 10% water: 90% methanol 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 18.4 min was collected and the solvents evaporated in vacuum.
  • Cytotoxic activity of Her-DSC-30.0378 [2.8] was evaluated with the HER2- positive tumor cell line SK-OV-3 (ovar) and a chemiluminescent BrdU incorporation assay (Roche Diagnostics) in vitro. Cell viability was determined after 72 h incubation with different concentrations of Her-DSC-30.0378 [2.8] at 37°C and 5% C02 by measurement of fixed and permealized cells with an anti-BrdU-HRP antibody in a BMG Labtech Optima microplate reader. EC 50 value of dose-response curve was calculated by Graphpad Prism 4.0 software. The EC 50 for Her-DSC-30.0378 [2.8] with SK-OV-3 cells was 4.1x10-1 1 M. (see Figure 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.

Description

A ATOXIN-CONJUGATES WITH IMPROVED LINKAGES
FIELD OF THE INVENTION
[001] The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.
BACKGROUND OF THE INVENTION
[002] Amatoxins are cyclic peptides composed of 8 amino acids. They can be isolated from Amanita phalloides mushrooms or prepared synthetically. Amatoxins specifically inhibit the DNA-dependent RNA polymerase II of mammalian cells, and thereby also the transcription and protein biosynthesis of the affected cells. Inhibition of transcription in a cell causes stop of growth and proliferation. Though not covalently bound, the complex between amanitin and RNA-polymerase II is very tight (KD = 3 nM). Dissociation of amanitin from the enzyme is a very slow process, thus making recovery of an affected cell unlikely. When the inhibition of transcription lasts too long, the cell will undergo programmed cell death (apoptosis).
[003] The use of amatoxins as cytotoxic moieties for tumour therapy had already been explored in 1981 by coupling an anti-Thy 1.2 antibody to a-amanitin using a linker attached to the indole ring of Trp (amino acid 4; see Figure 1) via diazotation (Davis & Preston, Science 1981 , 213, 1385-1388). Davis & Preston identified the site of attachment as position 7'. Morris & Venton demonstrated as well that substitution at position T results in a derivative, which maintains cytotoxic activity (Morris & Venton, Int. J. Peptide Protein Res. 1983, 21 419-430). [004] Patent application EP 1 859 811 A1 (published November 28, 2007) described conjugates, in which the γ C-atom of amatoxin amino acid 1 of β-amanitin was directly coupled, i.e. without a linker structure, to albumin or to monoclonal antibody HEA125, OKT3, or PA-1. Furthermore, the inhibitory effect of these conjugates on the proliferation of breast cancer cells (MCF-7), Burkitt's lymphoma cells (Raji), and T- lymphoma cells (Jurkat) was shown. The use of linkers was suggested, including linkers comprising elements such as amide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moieties and the like, but no such constructs were actually shown, and no more details, such as attachment sites on the amatoxins, were provided.
[005] Patent applications WO 2010/115629 and WO 2010/1 15630 (both published October 14, 2010) describe conjugates, where antibodies, such as anti- EpCAM antibodies such as humanized antibody huHEA125, are coupled to amatoxins via (i) the γ C-atom of amatoxin amino acid 1 , (ii) the 6' C-atom of amatoxin amino acid 4, or (iii) via the δ C-atom of amatoxin amino acid 3, in each case either directly or via a linker between the antibody and the amatoxins. The suggested linkers comprise elements such as amide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moieties and the like. Furthermore, the inhibitory effects of these conjugates on the proliferation of breast cancer cells (cell line MCF-7), pancreatic carcinoma (cell line Capan-1), colon cancer (cell line Colo205), and cholangiocarcinoma (cell line OZ) were shown.
[006] It is known that amatoxins are relatively non-toxic when coupled to large biomolecule carriers, such as antibody molecules, and that they exert their cytotoxic activity only after the biomolecule carrier is cleaved off. In light of the toxicity of amatoxins, particularly for liver cells, it is of outmost importance that amatoxin conjugates for targeted tumour therapy remain highly stable after administration in plasma, and that the release of the amatoxin occurs after internalization in the target cells. In this context, minor improvements of the conjugate stability may have drastic consequences for the therapeutic window and the safety of the amatoxin conjugates for therapeutic approaches. OBJECT OF THE INVENTION
[007] Thus, there was a high need in the prior art for target-binding moiety amatoxin conjugates that are stable in plasma, so that harmful side effects to non-target cells are minimized.
SUMMARY OF THE INVENTION
[008] The present invention is based on the unexpected observation that targeting moieties can be attached to amatoxins via linkers at additional attachment sites on tryptophan amino acid 4, namely positions 1'-N without interference with the interaction of such amatoxins with their target, the DNA-dependent RNA polymerase II of mammalian cells.
[009] Thus, the present invention relates to a conjugate comprising a target- binding moiety linked via a linker L to an amatoxin, or an analogue of an amatoxin, wherein the linker L is connected to the amatoxin via the 1'-N atom of amino acid 4.
[0010] In one aspect, the present invention relates to an amatoxin conjugate of Formula I
Figure imgf000005_0001
Formula I wherein:
R1 = H or OH;
R2 = H or OH;
R3 = NH2 or OH;
R4 = OH or OC1-6-alkyl; and
R5 = L-T; wherein L is a linker; and T is a target binding moiety.
[0011] In a further aspect, the present invention relates to a pharmaceutical composition comprising the conjugate according to the present invention.
[0012] In another aspect, the present invention relates to an amatoxin-conjugation molecule of Formula I, wherein R1 to R4 are as defined above; and wherein R5 = L-X; wherein L is a linker; and X is a leaving group that can be replaced by a nucleophilic group of a target-binding moiety, particularly a primary amine.
[0013] In yet another aspect, the present invention relates to a method for synthesizing a conjugate of the present invention, comprising the step of reacting an amatoxin-conjugation molecule of the present invention with a target-binding moiety comprising a nucleophilic group, particularly a primary amine.
BRIEF DESCRIPTION OF THE DRAWING
[0014] Fig. 1 shows the structural formulae of different amatoxins. The numbers in bold type (1 to 8) designate the standard numbering of the eight amino acids forming the amatoxin. The standard designations of the atoms in amino acids 1 , 3 and 4 are also shown (Greek letters a to γ, Greek letters a to δ, and numbers from 1 ' to 7', respectively).
[0015] Fig. 2 shows the cytotoxic activity of Her-DSC-30.0378 [2.8] on a HER2- positive tumor cell line in vitro in a BrdU assay after incubation for 72 h. DETAILED DESCRIPTION OF THE INVENTION
[0016] Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0017] Preferably, the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (lUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH- 4010 Basel, Switzerland).
[0018] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integer or step.
[0019] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, GenBank Accession Number sequence submissions etc.), whether supra or infra, is hereby incorporated by reference in its entirety to the extent possible under the respective patent law. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. [0020] The present invention will now be further described. In the following passages different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
[0021] Thus, the present invention relates to a conjugate comprising a target- binding moiety linked via a linker L to an amatoxin, or an analogue of an amatoxin, wherein the linker L is connected to the amatoxin via the 1 '-N atom of amino acid 4.
[0022] In the context of the present invention, the term "conjugate" refers to a molecule comprising at least two different molecules linked by a covalent bond.
[0023] The term "target-binding moiety", as used herein, refers to any molecule or part of a molecule that can specifically bind to a target molecule or target epitope. Preferred target-binding moieties in the context of the present application are (i) antibodies or antigen-binding fragments thereof; (ii) antibody-like proteins; and (iii) nucleic acid aptamers. "Target-binding moieties" suitable for use in the present invention typically have a molecular mass of 40 000 Da (40 kDa) or more.
[0024] As used herein, a first compound (e.g. an antibody) is considered to "specifically bind" to a second compound (e.g. an antigen, such as a target protein), if it has a dissociation constant KD to said second compound of 100 μΜ or less, preferably 50 Μ or less, preferably 30 μΜ or less, preferably 20 μΜ or less, preferably 10 μΜ or less, preferably 5 μΜ or less, more preferably 1 μΜ or less, more preferably 900 nM or less, more preferably 800 nM or less, more preferably 700 nM or less, more preferably 600 nM or less, more preferably 500 nM or less, more preferably 400 nM or less, more preferably 300 nM or less, more preferably 200 nM or less, even more preferably 100 nM or less, even more preferably 90 nM or less, even more preferably 80 nM or less, even more preferably 70 nM or less, even more preferably 60 nM or less, even more preferably 50 nM or less, even more preferably 40 nM or less, even more preferably 30 nM or less, even more preferably 20 nM or less, and even more preferably 10 nM or less.
[0025] In the context of the present application the terms "target molecule" and
"target epitope", respectively, refers to an antigen and an epitope of an antigen, respectively, that is specifically bound by a target-binding moiety. Preferably the target molecule is a tumour-associated antigen, in particular an antigen or an epitope which is present on the surface of one or more tumour cell types in an increased concentration and/or in a different steric configuration as compared to the surface of non-tumour cells Preferably, said antigen or epitope is present on the surface of one or more tumour cell types, but not on the surface of non-tumour cells. In particular embodiments, the target- binding moiety specifically binds to an epitope of HER-2/neu or epithelial cell adhesion molecule (EpCAM). In other embodiments, said antigen or epitope is preferentially expressed on cells involved in autoimmune diseases. In particular such embodiments, the target-binding moiety specifically binds to an epitope of the IL-6 receptor (IL-6R).
[0026] The term "antibody or antigen binding fragment thereof, as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain an antigen-binding site that immunospecifically binds an antigen. Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to a target molecule, e.g. to the target protein Her-2/neu or EpCAM. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2) or subclass of immunoglobulin molecule. "Antibodies and antigen-binding fragments thereof suitable for use in the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, human, humanized (in particular CDR-grafted), deimmunized, or chimeric antibodies, single chain antibodies (e.g. scFv), Fab fragments, F(ab')2 fragments, fragments produced by a Fab expression library, diabodies or tetrabodies (Holliger P. et al., 1993), nanobodies, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope- binding fragments of any of the above. [0027] In some embodiments the antigen-binding fragments are human antigen- binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide- linked Fvs (dsFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable domain(s) alone or in combination with the entirety or a portion of the following: hinge region, CL, CH1 , CH2, and CH3 domains. Also included in the invention are antigen- binding fragments also comprising any combination of variable domain(s) with a hinge region, CL, CH1 , CH2, and CH3 domains.
[0028] Antibodies usable in the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are from human, rodent (e.g. mouse, rat, guinea pig, or rabbit), chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog origin. It is particularly preferred that the antibodies are of human or murine origin. As used herein, "human antibodies" include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described for example in U.S. Patent No. 5,939,598 by Kucherlapati & Jakobovits.
[0029] The term "antibody-like protein" refers to a protein that has been engineered (e.g. by mutagenesis of loops) to specifically bind to a target molecule. Typically, such an antibody-like protein comprises at least one variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the antibody-like protein to levels comparable to that of an antibody. The length of the variable peptide loop typically consists of 10 to 20 amino acids. The scaffold protein may be any protein having good solubility properties. Preferably, the scaffold protein is a small globular protein. Antibody-like proteins include without limitation affibodies, anticalins, and designed ankyrin repeat proteins (for review see: Binz et al. 2005). Antibody-like proteins can be derived from large libraries of mutants, e.g. be panned from large phage display libraries and can be isolated in analogy to regular antibodies. Also, antibody-like binding proteins can be obtained by combinatorial mutagenesis of surface-exposed residues in globular proteins.
[0030] The term "nucleic acid aptamer" refers to a nucleic acid molecule that has been engineered through repeated rounds of in vitro selection or SELEX (systematic evolution of ligands by exponential enrichment) to bind to a target molecule (for a review see: Brody and Gold, 2000). The nucleic acid aptamer may be a DNA or RNA molecule. The aptamers may contain modifications, e.g. modified nucleotides such as 2'-fluorine- substituted pyrimidines.
[0031] As used herein, an "analogue" of a compound is structurally related but not identical to the compound and exhibits at least one activity of the compound. The compound to which the analogue is compared is known as the "parent" compound. The afore-mentioned activities include, without limitation: binding activity to another compound; inhibitory activity, e.g. enzyme inhibitory activity; toxic effects; activating activity, e.g. enzyme-activating activity. It is not required that the analogue exhibits such an activity to the same extent as the parent compound. A compound is regarded as an analogue within the context of the present application, if it exhibits the relevant activity to a degree of at least 1 % (more preferably at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, and more preferably at least 50%) of the activity of the parent compound. Thus, an "analogue of an amatoxin", as it is used herein, refers to a compound that is structurally related to any one of a-amanitin, β-amanitin, y-amanitin, ε-amanitin, amanin, amaninamide, amanullin, and amanullinic acid as shown in Fig. 1 and that exhibits at least 1 % (more preferably at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, and more preferably at least 50%) of the inhibitory activity against mammalian RNA polymerase II as compared to at least one of a-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanin, amaninamide, amanullin, and amanullinic acid. An "analogue of an amatoxin" suitable for use in the present invention may even exhibit a greater inhibitory activity against mammalian RNA polymerase II than any one of a-amanitin, β-amanitin, y-amanitin, ε-amanitin, amanin, amaninamide, amanullin, or amanullinic acid. The inhibitory activity might be measured by determining the concentration at which 50% inhibition occurs (IC50 value). The inhibitory activity against mammalian RNA polymerase II can be determined indirectly by measuring the inhibitory activity on cell proliferation. A suitable assay for measuring inhibition of cell proliferation is described in the examples.
[0032] A "semisynthetic analogue" refers to an analogue that has been obtained by chemical synthesis using compounds from natural sources (e.g. plant materials, bacterial cultures, or cell cultures) as starting material. Typically, a "semisynthetic analogue" of the present invention has been synthesized starting from a compound isolated from a mushroom of the Amanita family. In contrast, a "synthetic analogue" refers to an analogue synthesized by so-called total synthesis from small (typically petrochemical) building blocks. Usually, this total synthesis is carried out without the aid of biological processes.
[0033] As used herein, an "aptamer conjugate" refers to a target-binding moiety toxin conjugate in which the target-binding moiety is a nucleic acid aptamer according to above alternative (iii).
[0034] A "linker" in the context of the present invention refers to a molecule that is connecting two components, each being attached to one end of the linker, and which increases the distance between two components and alleviates steric interference between these components, such as in the present case between the target-binding moiety and the amatoxin. In the absence of a linker, a direct linkage of amatoxin to the target-binding moiety may decrease the ability of the amatoxin to interact with RNA polymerase II. In particular embodiments, a linker has a continuous chains of between 1 and 30 atoms (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 atoms; thus, in the context of the present invention, the term "between" is used so that the borders mentioned are included) in its backbone, i.e. the length of the linker is defined as the shortest connection as measured by the number of atoms or bonds between the amatoxin moiety and the target-binding moiety, wherein one side of the linker backbone has been reacted with the amatoxin and, the other side with a target-binding moiety. In the context of the present invention, a linker preferably is an Ci-2o-alkylene, d-20-heteroalkylene, C2.20-alkenylene, C2-2o- heteroalkenylene, C2-2o-alkynylene, C2-2o-heteroalkynylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or a heteroaralkylene group, optionally substituted. The linker may contain one or more structural elements such as carboxamide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moieties and the like. The linker may also contain combinations of two or more of these structural elements. Each one of these structural elements may be present in the linker more than once, e.g. twice, three times, four times, five times, or six times. In some embodiments the linker may comprise a disulfide bond. It is understood that the linker has to be attached either in a single step or in two or more subsequent steps to the amatoxin and the target-binding moiety. To that end the linker to be will carry two groups, preferably at a proximal and distal end, which can (i) form a covalent bond to a group present in one of the components to be linked, preferably an activated group on an amatoxin or the target binding-peptide or (ii) which is or can be activated to form a covalent bond with a group on an amatoxin. Accordingly, it is preferred that chemical groups are at the distal and proximal end of the linker, which are the result of such a coupling reaction, e.g. an ester, an ether, a urethane, a peptide bond etc.
[0035] In the context of the present invention, the term "amatoxin" includes all cyclic peptides composed of 8 amino acids as isolated from the genus Amanita and described in Wieland, T. and Faulstich H. (Wieland T, Faulstich H., CRC Crit Rev Biochem. 1978 Dec;5(3): 185-260), and furthermore includes all chemical derivatives thereof; further all semisynthetic analogues thereof; further all synthetic analogues thereof built from building blocks according to the master structure of the natural compounds (cyclic, 8 amino acids), further all synthetic or semisynthetic analogues containing non-hydroxylated amino acids instead of the hydroxylated amino acids, further all synthetic or semisynthetic analogues, in which the thioether sulfoxide moiety is replaced by a sulfide, sulfone, or by atoms different from sulfur, e.g. a carbon atom as in a carbaanalogue of amanitin, in each case wherein any such derivative or analogue is functionally active by inhibiting mammalian RNA polymerase II. [0036] Functionally, amatoxins are defined as peptides or depsipeptides that inhibit mammalian RNA polymerase II. Preferred amatoxins are those with a functional group (e.g. a carboxylic group, an amino group, a hydroxy group, a thiol or a thiol- capturing group) that can be reacted with linker molecules or target-binding moieties as defined above. Amatoxins which are particularly suitable for the conjugates of the present invention are ct-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanin, amaninamide, amanullin, and amanullinic acid as shown in Fig. 1 as well as salts, chemical derivatives, semisynthetic analogues, and synthetic analogues thereof. Particularly preferred amatoxins for use in the present invention are a-amanitin, β- amanitin, and amaninamide.
[0037] As used herein, a "chemical derivative" (or short: a "derivative") of a compound refers to a species having a chemical structure that is similar to the compound, yet containing at least one chemical group not present in the compound and/or deficient of at least one chemical group that is present in the compound. The compound to which the derivative is compared is known as the "parent" compound. Typically, a "derivative" may be produced from the parent compound in one or more chemical reaction steps.
[0038] In particular embodiments of the present invention, the amatoxin is selected from a-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanin, amaninamide, amanullin, or amanullinic acid, or from salts or analogues thereof.
[0039] In one aspect, the present invention relates to an amatoxin conjugate of
Formula I
Figure imgf000015_0001
Formula I wherein:
R1 = H or OH;
R2 = H or OH;
R3 = NH2 or OH;
R4 = OH or OCi-e-alkyl; and
R5 = L-T; wherein L is a linker; and T is a target binding moiety.
[0040] In a particular embodiment, the amatoxin conjugate of Formula I is a derivative of a-amanitin (R1 = OH; R2 = OH; and R3 = NH2).
[0041] In a particular embodiment, R4 is O-Me.
[0042] In a particular embodiment, the linker is connected to the target-binding moiety via a urea moiety.
[0043] In the context of the present invention the term "connected to the target- binding moiety via a urea moiety" refers to a connection between the linker and the target-binding moiety, where the target-binding moiety is directly attached to the linker via an -NH-C(O)-NH- group. [0044] In particular embodiments of the present invention, the target-binding moiety is connected to the linker L via an amino group present in the target-binding moiety, wherein said amino group forms part of said urea moiety.
[0045] In particular embodiments, the linker has a length of between 1 and 8 atoms, particularly between 1 and 6, more particularly between 1 and 4, and most particularly between 2 and 4 atoms. Thus, an ethylene linker has a linker length of 2 atoms, a propylene linker of 3 atoms, and a butylene linker of 4 atoms
[0046] In particular embodiments of the present invention, the linker L comprises one or more groups, particularly one, two or three groups, selected from the list of: alkylene, alkenylene, alkynylene, cycloalkylene, heteroalkylene, heteroalkenylene, heteroalkynylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, and a heteroaralkylene group, wherein each group may optionally be independently substituted.
[0047] The term "alkylene" refers to a bivalent straight chain saturated hydrocarbon groups having from 1 to 20 carbon atoms, including groups having from 1 to 10 carbon atoms. In certain embodiments, alkylene groups may be lower alkylene groups. The term "lower alkylene" refers to alkylene groups having from 1 to 6 carbon atoms, and in certain embodiments from 1 to 5 or 1 to 4 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2-CH2-), n-propylene, n-butylene, n-pentylene, and n-hexylene.
[0048] The term "alkenylene" refers to bivalent straight chain groups having 2 to 20 carbon atoms, wherein at least one of the carbon-carbon bonds is a double bond, while other bonds may be single bonds or further double bonds. The term "alkynylene" herein refers to groups having 2 to 20 carbon atoms, wherein at least one of the carbon- carbon bonds is a triple bond, while other bonds may be single, double or further triple bonds. Examples of alkenylene groups include ethenylene (-CH=CH-), 1-propenylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene, and the like. Examples of alkynylene groups include ethynylene, 1-propynylene, 2-propynylene, and so forth.
[0049] As used herein, "cycloalkylene" is intended to refer to a bivalent ring being part of any stable monocyclic or polycyclic system, where such ring has between 3 and 12 carbon atoms, but no heteroatom, and where such ring is fully saturated, and the term "cycloalkenylene" is intended to refer to a bivalent ring being part of any stable monocyclic or polycyclic system, where such ring has between 3 and 12 carbon atoms, but no heteroatom, and where such ring is at least partially unsaturated (but excluding any arylene ring). Examples of cycloalkylenes include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and cycloheptylene. Examples of cycloalkenylenes include, but are not limited to, cyclopentenylene and cyclohexenylene.
[0050] As used herein, the terms "heterocycloalkylene" and
"heterocycloalkenylene" are intended to refer to a bivalent ring being part of any stable monocyclic or polycyclic ring system, where such ring has between 3 and about 12 atoms, and where such ring consists of carbon atoms and at least one heteroatom, particularly at least one heteroatom independently selected from the group consisting of N, O and S, with heterocycloalkylene referring to such a ring that is fully saturated, and heterocycloalkenylene referring to a ring that is at least partially unsaturated (but excluding any arylene or heteroarylene ring).
[0051] The term "arylene" is intended to mean a bivalent ring or ring system being part of any stable monocyclic or polycyclic system, where such ring or ring system has between 3 and 20 carbon atoms, but has no heteroatom, which ring or ring system consists of an aromatic moiety as defined by the "4n+2" π electron rule, including phenylene.
[0052] As used herein, the term "heteroarylene" refers to a bivalent ring or ring system being part of any stable mono- or polycyclic system, where such ring or ring system has between 3 and 20 atoms, which ring or ring system consists of an aromatic moiety as defined by the "4n+2" π electron rule and contains carbon atoms and one or more nitrogen, sulfur, and/or oxygen heteroatoms.
[0053] In the context of the present invention, the term "substituted" is intended to indicate that one or more hydrogens present in the backbone of a linker is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency, or that of the appropriate atom of the group that is substituted, is not exceeded, and that the substitution results in a stable compound. The term "optionally substituted" is intended to mean that the linker is either unsubstituted or substituted, as defined herein, with one or more substituents, as defined herein. When a substituent is a keto (or oxo, i.e. =0) group, a thio or imino group or the like, then two hydrogens on the linker backbone atom are replaced. Exemplary substituents include, for example, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, aroyl, heteroaroyl, carboxyl, alkoxy, aryloxy, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, halogen, (thio)ester, cyano, phosphoryl, amino, imino, (thio)amido, sulfhydryl, alkylthio, acylthio, sulfonyl, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, nitro, azido, haloalkyl, inducing perfluoroalkyl (such as trifluoromethyl), haloalkoxy, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfonylamino, arylsulfonoamino, phosphoryl, phosphate, phosphonate, phosphinate, alkylcarboxy, alkylcarboxyamide, oxo, hydroxy, mercapto, amino (optionally mono- or di-substituted, e.g. by alkyl, aryl, or heteroaryl), imino, carboxamide, carbamoyl (optionally mono- or di-substituted, e.g. by alkyl, aryl, or heteroaryl), amidino, aminosulfonyl, acylamino, aroylamino, (thio)ureido, arylthio)ureido, alkyl(thio)ureido, cycloalkyl(thio)ureido, aryloxy, aralkoxy, or -0(CH2)n-OH, -O(CH2)n- NH2, -0(CH2)nCOOH, -(CH2)nCOOH, -C(0)0(CH2)nR, -(CH2)nN(H)C(0)OR, or - N(R)S(0)2R wherein n is 1-4 and R is independently selected from hydrogen, -alkyl, - alkenyl, -alkynyl, -cycloalkyl, -cycloalkenyl, -(C-linked-heterocycloalkyl), -(C-linked- heterocycloalkenyl), -aryl, and -heteroaryl, with multiple degrees of substitution being allowed. It will be understood by those skilled in the art that substituents, such as heterocycloalkyl, aryl, heteroaryl, alkyl, etc., or functional groups such as -OH, -NHR etc., can themselves be substituted, if appropriate. It will also be understood by those skilled in the art that the substituted moieties themselves can be substituted as well when appropriate. [0054] In particular embodiments of the present invention, wherein the linker L comprises m groups selected from the list of: alkylene, alkenylene, alkynylene, cycloalkylene, heteroalkylene, heteroalkenylene, heteroalkynylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, and a heteroaralkylene group, wherein each group may optionally be independently substituted, the linker further comprises n moiety independently selected from one of the following moieties: a disulfide (-S-S-), an ether (- 0-), a thioether (-S-), an amine (-NH-), an ester (-0-C(=0)- or -C(=0)-0-), a carboxamide (-NH-C(=0)- or -C(=0)-NH-), a urethane (-NH-C(=0)-0- or -0-C(=0)-NH- ), and a urea moiety (-NH-C(=0)-NH-), wherein m = n+1. In particular embodiments, m is 2 and n is 1 , or m is 3 and n is 2. In particular embodiments, the linker comprises 2 or 3 unsubstituted alkylene groups, and 1 or 2, respectively, disulfide, ether, thioether, amine, ester, carboxamide, urethane or urea moieties linking the unsubstituted alkylene groups.
[0055] In particular embodiments of the present invention the target-binding moiety specifically binds to an epitope that is present on a tumour cell.
[0056] In particular embodiments of the present invention the target-binding moiety specifically binds to an epitope of Her-2/neu or epithelial cell adhesion molecule (EpCAM).
[0057] In particular embodiments of the present invention the target-binding moiety is selected from the group consisting of: antibody or antigen-binding fragment thereof; antibody-like protein; and nucleic acid aptamer.
[0058] In particular embodiments of the present invention the antibody or the antigen-binding fragment thereof is selected from a diabody, a tetrabody, a nanobody, a chimeric antibody, a deimmunized antibody, a humanized antibody or a human antibody.
[0059] In particular embodiments of the present invention the antigen binding fragment is selected from the group consisting of Fab, F(ab')2, Fd, Fv, single-chain Fv, and disulfide-linked Fvs (dsFv). [0060] In particular embodiments, the antibody is herceptin or HEA125, or an antibody fragment comprising the antigen binding fragment of herceptin or ΗΕΞΑ125.
[0061] In particular embodiments, more than one amatoxin molecule is coupled to one target-binding moiety. An increase of the number of amatoxins per conjugate will also increase the toxicity. Accordingly, in a particular embodiment the ratio of target- binding moiety to amatoxin is between 1 target-binding moiety to between 2 and 15 amatoxin molecules, particularly 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, or 15. For the purpose of the calculation of the ratio in case of antibody dimers such as IgGs, the dimer is considered as one target-binding moiety.
[0062] In particular embodiments of the present invention, the conjugate is for use as a medicament.
[0063] In particular embodiments of the present invention, the conjugate is for use in the treatment of cancer in a patient, wherein the cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma.
[0064] In yet another aspect, the present invention relates to a method for the treatment of cancer in a patient, wherein the cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma, comprising the step of administering a conjugate of the present invention to a patient in need thereof.
[0065] As used herein, a "patient" means any mammal or bird who may benefit from a treatment with the target-binding moiety toxin conjugates described herein. Preferably, a "patient" is selected from the group consisting of laboratory animals (e.g. mouse or rat), domestic animals (including e.g. guinea pig, rabbit, chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog), or primates including human beings. It is particularly preferred that the "patient" is a human being.
[0066] As used herein, "treat", "treating" or "treatment" of a disease or disorder means accomplishing one or more of the following: (a) reducing the severity of the disorder; (b) limiting or preventing development of symptoms characteristic of the disorder(s) being treated; (c) inhibiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting or preventing recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder(s).
[0067] As used herein, the treatment may comprise administering a conjugate or a pharmaceutical composition according to the present invention to a patient, wherein "administering" includes in vivo administration, as well as administration directly to tissue ex vivo, such as vein grafts.
[0068] In particular embodiments, a therapeutically effective amount of the conjugate of the present invention is used.
[0069] A "therapeutically effective amount" is an amount of a therapeutic agent sufficient to achieve the intended purpose. The effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration. The effective amount in each individual case may be determined empirically by a skilled artisan according to established methods in the art.
[0070] In a further aspect, the present invention relates to a pharmaceutical composition comprising the conjugate according to the present invention, further comprising one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives. [0071] "Pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
[0072] In particular embodiments, the pharmaceutical composition is used in the form of a systemically administered medicament. This includes parenterals, which comprise among others injectables and infusions. Injectables are formulated either in the form of ampoules or as so called ready-for-use injectables, e.g. ready-to-use syringes or single-use syringes and aside from this in puncturable flasks for multiple withdrawal. The administration of injectables can be in the form of subcutaneous (s.c), intramuscular (i.m.), intravenous (i.v.) or intracutaneous (i.e.) application. In particular, it is possible to produce the respectively suitable injection formulations as a suspension of crystals, solutions, nanoparticular or a colloid dispersed systems like, e.g. hydrosols.
[0073] Injectable formulations can further be produced as concentrates, which can be dissolved or dispersed with aqueous isotonic diluents. The infusion can also be prepared in form of isotonic solutions, fatty emulsions, liposomal formulations and micro- emulsions. Similar to injectables, infusion formulations can also be prepared in the form of concentrates for dilution. Injectable formulations can also be applied in the form of permanent infusions both in in-patient and ambulant therapy, e.g. by way of mini-pumps.
[0074] It is possible to add to parenteral drug formulations, for example, albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances to influence the adsorption of the target-binding moiety toxin conjugates of the invention to proteins or polymers or they can also be added with the aim to reduce the adsorption of the target-binding moiety toxin conjugates of the invention to materials like injection instruments or packaging-materials, for example, plastic or glass.
[0075] The target-binding moiety toxin conjugates of the invention can be bound to microcarriers or nanoparticles in parenterals like, for example, to finely dispersed particles based on poly(meth)acrylates, polylactates, polyglycolates, polyamino acids or polyether urethanes. Parenteral formulations can also be modified as depot preparations, e.g. based on the "multiple unit principle", if the target-binding moiety toxin conjugates of the invention are introduced in finely dispersed, dispersed and suspended form, respectively, or as a suspension of crystals in the medicament or based on the "single unit principle" if the target-binding moiety toxin conjugate of the invention is enclosed in a formulation, e.g. in a tablet or a rod which is subsequently implanted. These implants or depot medicaments in single unit and multiple unit formulations often consist of so called biodegradable polymers like e.g. polyesters of lactic acid and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.
[0076] Adjuvants and carriers added during the production of the pharmaceutical compositions of the present invention formulated as parenterals are preferably aqua sterilisata (sterilized water), pH value influencing substances like, e.g. organic or inorganic acids or bases as well as salts thereof, buffering substances for adjusting pH values, substances for isotonization like e.g. sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides and surfactants, respectively, and emulsifiers like, e.g. partial esters of fatty acids of polyoxyethylene sorbitans (for example, Tween®) or, e.g. fatty acid esters of polyoxyethylenes (for example, Cremophor®), fatty oils like, e.g. peanut oil, soybean oil or castor oil, synthetic esters of fatty acids like, e.g. ethyl oleate, isopropyl myristate and neutral oil (for example, Miglyol®) as well as polymeric adjuvants like, e.g. gelatine, dextran, polyvinylpyrrolidone, additives which increase the solubility of organic solvents like, e.g. propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex forming substances like, e.g. citrate and urea, preservatives like, e.g. benzoic acid hydroxypropyl ester and methyl ester, benzyl alcohol, antioxidants like e.g. sodium sulfite and stabilizers like e.g. EDTA.
[0077] When formulating the pharmaceutical compositions of the present invention as suspensions in a preferred embodiment thickening agents to prevent the setting of the target-binding moiety toxin conjugates of the invention or, tensides and polyelectrolytes to assure the resuspendability of sediments and/or complex forming agents like, for example, EDTA are added. It is also possible to achieve complexes of the active ingredient with various polymers. Examples of such polymers are polyethylene glycol, polystyrol, carboxymethyl cellulose, Pluronics® or polyethylene glycol sorbit fatty acid ester. The target-binding moiety toxin conjugates of the invention can also be incorporated in liquid formulations in the form of inclusion compounds e.g. with cyclodextrins. In particular embodiments dispersing agents can be added as further adjuvants. For the production of lyophilisates scaffolding agents like mannite, dextran, saccharose, human albumin, lactose, PVP or varieties of gelatine can be used.
[0078] In a further aspect the present invention is directed to a method of treating pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, or malignant lymphoma in a patient in need thereof, comprising administering to the patient an effective amount of a conjugate or pharmaceutical composition of the present invention.
[0079] In another aspect, the present invention relates to an amatoxin-conjugation molecule comprising a leaving group X attached to a linker L connected to an amatoxin, or an analogue of an amatoxin, wherein the linker L is connected to the amatoxin via the T-N atom of amino acid 4.
[0080] In certain embodiments of such aspect, the present invention relates to an amatoxin-conjugation molecule of Formula I
Figure imgf000025_0001
Formula I wherein:
R1 = H or OH;
R2 = H or OH;
R3 = NH2 or OH;
R4 = OH or OC1-6-alkyl; and
R5 = L-X; wherein L is a linker; and X is a leaving group that can be replaced by a nucleophilic group of a target-binding moiety.
[0081] In a particular embodiment, the nucleophilic group is a primary amine.
[0082] In a particular embodiment, the amatoxin-conjugation molecule of Formula
I is a derivative of a-amanitin (R1 = OH; R2 = OH; and R3 = NH2).
[0083] In a particular embodiment, R4 is O-Me.
[0084] In particular embodiments, the linker has a length of between 1 and 8 atoms, particularly between 1 and 6, more particularly between 1 and 4, and most particularly between 2 and 4 atoms. [0085] In certain embodiments, the linker L is an alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or a heteroaralkylene group, optionally substituted.
[0086] In certain embodiments, the linker L comprises a moiety selected from one of the following moieties: a disulfide, an ether, an amine, an ester, a carboxamide, a urethane, and a urea moiety.
[0087] In certain embodiments, the functional group X is selected from: 'butyloxy, succinimidyloxy, 1-0-succinimidyloxy-3-sulfonate (Sulfo-NHS), 0-(4-nitrophenyloxy), O- (3-nitrophenyloxy), 0-(2,4-dinitrophenyloxy), 0-(2,4-dichloro-6-nitrophenyloxy), pentafluorophenyloxy, pentachlorophenyloxy, 0-(2,4,5-trichlorophenyloxy), 0-(3,4- dihydro-3-hydroxy-4-oxo-1 ,2,3-benzotriazine-3-yl), 0-(endo-1 -hydroxy-5-norbornene-2,3- dicarboximide-1-yl), 1-phthalimidoyloxy, 1-benzotriazolyloxy, 1 -(7-aza-benzotriazolyl)oxy, and N-imidazolyl.
[0088] In yet another aspect, the present invention relates to a method for synthesizing an amatoxin conjugate of the present invention, comprising the step of reacting an amatoxin-conjugation molecule of the present invention with a target-binding moiety comprising a nucleophilic group, particularly a primary amine.
[0089] In yet another aspect, the present invention relates to a method for synthesizing an amatoxin-conjugation molecule of the present invention, comprising the step of (i) reacting an amatoxin with a linker molecule Y-L-X, wherein Y is a moiety that can react with 1'-N atom of amino acid 4 of the amatoxin, and wherein X is a is a leaving group that can be replaced by a nucleophilic group of a target-binding moiety, particularly by a primary amine.
[0090] In yet another aspect, the present invention relates to a method for synthesizing an amatoxin-conjugation molecule of the present invention, comprising the step of (i) reacting an amatoxin with a linker molecule Y-L-Z, wherein Y is a moiety that can react with 1'-N atom of amino acid 4 of the amatoxin, and wherein Z is a moiety, which can be converted into a leaving group X, that can be replaced by a nucleophilic group of a target-binding moiety, particularly by a primary amine.
[0091] In certain embodiments, the amatoxin is reacted with a linker molecule Y-
L-X, or Y-L-Z, respectively, wherein Y is selected from the group consisting of: O-Tos (O- Tos = tosylate); I; Br, and O-Tf (O-Tf = triflate). In certain such embodiments, the amatoxin is treated with Y-L-X, or Y-L-Z, respectively, in the presence of a base, particularly KO'Bu, LiOH or NaH, in a solvent, particularly in a polar, aprotic solvent such as DMF, D SO, or NMP.
[0092] In certain embodiments, the group Z is a protected primary amino group, particularly NH-C(=0)OtBu. In particular such embodiments, the protected primary amino is first deprotected and then activated by a carbonic acid derivative, such as dihydroxysuccinimido carbonate (DSC).
[0093] In another aspect, the present invention relates to an amatoxin-linker molecule of Formula I, wherein R1 to R4 are as defined above; and wherein R5 = L-Z; wherein L is a linker; and wherein Z is a moiety, which can be converted into a leaving group X, that can be replaced by a nucleophilic group of a target-binding moiety, particularly by a primary amine.
EXAMPLES
In the following, the invention is explained in more detail by non-limiting examples:
Example 1
Synthesis of NT Linker Amanitines
1.1 Preparation of N1'-6-aminohexyl-6'-0-methyl-a-amanitin (HDP 30.0378)
Figure imgf000028_0001
O-methyl-a-amanitin HDP 30.0368
[0094] 4.86 mg (5.21 pmol) O-methyl-a-amanitin were dissolved in 500 μΙ dry DMSO. Under argon, 1 1 .68 mg (41 .67 μιτιοΙ) Boc-aminohexyl bromide and 100 μΙ of a 52.1 mM solution of potassium t-butanolate in DMSO were added. Additional potassium t-butanolate portions of the 5.21 mM stock solution were added: 50 μΙ at 1.5 h; 50 μΙ at 4 h, and 50 μΙ at 6 h. After 19 h, 100 μΙ potassium t-butanolate and 1 1 .96 mg (41 .67 pmol) Boc-aminohexyl bromide were added. After 21 h, the reaction mixture was quenched with 104 μΙ of a 100 mM acetic acid solution in DMSO. The crude product was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μιη, 250 x 20 mm, with methanol/water ( 0.05% TFA), flow: 26.0 ml/min, detection at λ = 295 nm. Solvent A: 95% water: 5% methanol, 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol, 0.05% trifluoroacetic acid. Gradient: 0-5 min 100% A; 5-20 min 0% A; 20-25 min 0% A; 25-27 min 100% A; 27-35 min 100% A; the fraction with the retention time of 19.2-20.9 min was collected and the solvents evaporated to a solid. [0095] 4.81 mg (81 %) HDP 30.0368; MS: 1133 (M+H+).
Figure imgf000029_0001
HDP30.0368 HDP 30.0378
[0096] 4.75 mg (4.19 μηιοΙ) HDP 30.0368 were dissolved in 200 μΙ trifluoroacetic acid and stirred for 2 min. The reaction mixture was evaporated to dryness at ambient temperature and co-evaporated with 1000 μΙ toluene and 10000 μΙ acetonitrile. The crude product was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μηη, 250 x 20 mm, with methanol/water (0.05% TFA), flow: 26.0 ml/min, detection at λ = 295 nm. Solvent A: 95% water: 5% methanol, 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol, 0.05% trifluoroacetic acid. Gradient: 0-5 min 100% A; 5-20 min 0% A; 20- 25 min 0% A; 25-27 min 100% A; 27-35 min 100% A; the fraction with the retention time of 14.9-15.5 min was collected and the solvents evaporated and freeze dried to a powder.
[0097] 1.54mg (32%) HDP 30.0378; MS: 1033 (M+H+).
1.2 Preparation of N1'-8-aminooctyl-6'-0-methyl-a-amanitin (HDP 30.0516)
Figure imgf000030_0001
O-methyl-a-amanitin HDP 30.0496
[0098] 12.43 mg (13.32 μιηοΙ) O-methyl-a-methylamanitin were dissolved in 750 μΙ dry DMSO. 40.00 mg (129.76 pmol) N-Boc-8-aminobromoactane and 120 μΙ of a 0.1 M LiOH solution in DMSO/water 1 :1 were added. The reaction mixture was stirred at room temperature under argon. After 18 h additional 80 μΙ LiOH were added followed by 40 μΙ 36 h, 50 μΙ 39 h and 80 μΙ 44 h later. DMSO and water were removed in high vacuum and the residue was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μπι, 250 x 20 mm, with methanol/water (0.05% TFA), flow: 10.0 ml/min, detection at λ = 230nm. Solvent A: 95% water: 5% methanol, 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol, 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A; the fraction with the retention time of 37.0 min was collected and the solvents evaporated in vacuum.
[0099] 3.96 mg (26%) HDP 30.0496 as a white powder. MS: 1160 (M+H+).
Figure imgf000031_0001
HDP30.0496 HDP 30.0516
[00100] 3.96 mg (3.41 prnol) HDP 30.0496 were dissolved in 300 μΙ trifluoroacetic acid and stirred for 2.5 min at room temperature. The reaction mixture was diluted with 1000 μΙ toluene and evaporated to dryness at ambient temperature. The residue was co- evaporated two times with the same volume of toluene. The residue was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μπι, 250 x 20 mm, with methanol/water (0.05% TFA), flow: 10.0 ml/min, detection at λ = 230 nm. Solvent A: 95% water: 5% methanol, 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol, 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A; the fraction with the retention time of 21.0 min was collected and the solvents evaporated in vacuum.
[00101] 2.66mg (74%) HDP 30.0516 as a white powder. MS: 1060 (M+H+); 1083 (M+Na+).
1. Preparation of N1'-6-aminobutyl-6'-0-methyl-a-amanitin HDP 30.0592
Figure imgf000032_0001
O-methyl-a-amanitin HDP 30.0587
[00102] 1 1.88 mg (12.74 μηιοΙ) O-methyl-a-amanitin were dissolved in 500 μΙ dry DMSO. Under argon, 20.00 mg (79.32 pmol) Boc-aminobutyl bromide and 83.4 μΙ of a 0.25 mM solution of potassium t-butanolate were added. Additional portions of 20.00 mg (79.32 pmol) Boc-aminobutyl bromide and 83.4 μΙ potassium t-butanolate were added at each hour during the reaction period. The reaction mixture was quenched with 100 μΙ of acetic acid after 8 h. The crude product was purified on a LaPrep-HPLC: column: Phenomenex Luna C18, 10 μιη, 250x20 mm, with methanol/water, flow: 15.0 ml/min, detection at λ = 290 nm. Solvent A: 100% water. Solvent B: 100% methanol. Gradient: 0 min 95% A; 0-5 min 50% A; 5-10 min 30% A; 10-20 min 20% A; 20-45 min 5% A. The fraction with the retention time of 16.5 min was collected and the solvents evaporated.
[00103] 5.10 mg (36%) HDP 30.0587; MS: 1104.5 (M+H+).
Figure imgf000033_0001
[00104] 5.10 mg (4.61 μιηοΙ) HDP 30.0587 were dissolved in 1000 μΙ trifluoroacetic acid and stirred for 2 min. The reaction mixture was evaporated to dryness at ambient temperature and dried in vacuum. The crude product was purified on a LaPrep-HPLC: column: column: Phenomenex Luna C18, 10 μητι, 250x20 mm, with methanol/water, flow: 15.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol 0.05% trifluoroacetic acid. Solvent B: 5% water: 95% methanol 0.05% trifluoroacetic acid. Gradient: 0 min 100% A; 0-5 min 50% A; 5-10 min 30% A; 10-20 min 20% A; 20-45 min 0% A. The fraction with the retention time of 10.0 min was collected and the solvents evaporated.
[00105] 3.48 mg (75%) HDP 30.0592 white powder MS: 1004.4 (M+H+).
Preparation of Nl'-e-aminopentyl-e'-O-methyl-a-amanitin HDP 30.0644
Figure imgf000034_0001
O-methyl-a-amanitin HDP 30.0636
[00106] 8.40 mg (9.00 μιηοΓ) O-methyl-a-methylamanitin were dissolved in 400 μΙ dry DMSO. 29.00 mg (108.94 pmol) N-Boc-5-aminobromopentane and 14.20 μΙ of a 1 M LiOH solution in water were added. The reaction mixture was stirred at room temperature under argon. After 4 h additional 7.10 μΙ LiOH were added. The reaction mixture was quenched with 100 μΙ acetic acid after 6 h, and DMSO and water were removed in high vacuum. The residue was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μιη, 250x20 mm, with methanol/water Kromasil 100-C18, 10 μπι, 250x20 mm, with methanol/water, flow: 10.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol. Solvent B: 5% water: 95% methanol. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 30 min was collected and the solvents evaporated in vacuum.
[00107] HDP 30.0636 was obtained as a white powder. MS: 1 118.5 (M+H+). The product was used for the next step.
Figure imgf000035_0001
HDP30.0636 HDP 30.0644
[00108] HDP 30.0636 was dissolved in 400 μΙ trifluoroacetic acid and stirred for 5 min at room temperature. The reaction mixture was diluted with 1000 μΙ toluene and evaporated to dryness at ambient temperature. The solid residue was co-evaporated with the same volume of toluene (2x) and purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 pm, 250x20 mm, with methanol/water (0.05% TFA), flow: 10.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 18.0 min was collected and the solvents evaporated in vacuum.
[00109] 0.51 mg white powder (6%, overall yield) HDP 30.0644. MS: 1018.4 (M+H+).
Preparation of N1-t-butylpropionyl-6-0-methyl-a-amanitin HDP 30.0678
Figure imgf000036_0001
O-methyl-a-amanitin HDP 30.0677
[00110] 7.04 mg (7.55 μητιοΙ) O-methyl-a-methylamanitin were dissolved in 500 μΙ dry DMSO. 14.10 μΙ of a 1 M LiOH solution in water were added. The reaction mixture was stirred at room temperature under argon for 5 min and 20 μΙ 1-chloropropionicacid-t- butylester were added. After 1 h additional 20.00 μΙ LiOH and 20.00 μΙ 1- chloropropionicacid-t-butylester were added. The reaction mixture was quenched with 100 μΙ acetic acid after 2 h. DMSO and water were removed in high vacuum and the residue was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 pm, 250x20 mm, with methanol/water, flow: 10.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol. Solvent B: 5% water: 95% methanol. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 26.0 min was collected and the solvents evaporated in vacuum.
[0011 1] HDP 30.0677 was obtained as a white solid. MS: 1047.4 (M+H+). The residue was used for the next step.
Figure imgf000037_0001
[00112] HDP 30.0677 was dissolved in 500 μΙ trifluoroacetic acid and stirred for 4 min at room temperature. The reaction mixture was evaporated to dryness at ambient temperature. The residue was co-evaporated two times with 5 ml toluene. The white residue was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 pm, 250x20 mm, with methanol/water (0.05% TFA), flow: 10.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 18.0 min was collected and the solvents evaporated in vacuum.
[00113] 1.90mg (25%) HDP 30.0678 white powder. MS: 991.3 (M+H+).
1.6 Preparation of NI'^-Boc-aminomethylbenzyl-e'-O-methyl-a-amanitin HDP 30.0683
Figure imgf000038_0001
O-methyl-ct-amanitin HDP 30.0680
[00114] 8.90 mg (9.54 μιτιοΙ) O-methyl-a-methylamanitin were dissolved in 500 μΙ dry DMSO. 21 ,4 μΙ of a 1 M LiOH solution in water were added. The reaction mixture was stirred at room temperature under argon for 10 min and 20,0 mg (78.40 μηιοΙ) 4-Boc aminobenzyl chloride were added at once. After 18 h the reaction mixture was quenched with 100 μΙ acetic acid. DMSO and water were removed in high vacuum and the residue was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μιτι, 250x20 mm, with methanol/water Kromasil 100-C18, 10 μιτι, 250x20 mm, with methanol/water, flow: 10.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol. Solvent B: 5% water: 95% methanol. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20- 50 min 20% A. The fraction with the retention time of 34,0 min was collected and the solvents evaporated in vacuum, which gave HDP 30.0680 as a white residue. MS: 1 152.5 (M+H+). The product was used for the next step.
Figure imgf000039_0001
[00115] HDP 30.0680 was dissolved in 500 μΙ trifluoroacetic acid and stirred for 10 min at room temperature and evaporated to dryness at ambient temperature. The residue was co-evaporated two times with 4 ml toluene. The white powder was purified on a LaPrep-HPLC: column: Kromasil 100-C18, 10 μπι, 250x20 mm, with methanol/water (0.05% TFA), flow: 10.0 ml/min, detection at λ = 290 nm. Solvent A: 95% water: 5% methanol 0.05% trifluoroacetic acid. Solvent B: 10% water: 90% methanol 0.05% trifluoroacetic acid. Gradient: 0-5 min 80% A; 5-10 min 50% A; 10-20 min 30% A; 20-50 min 20% A. The fraction with the retention time of 18.4 min was collected and the solvents evaporated in vacuum.
[00116] 3.15 mg (31%) HDP 30.0683 as a white powder. MS: 1052.4 (M+H+).
Example 2
Synthesis of Amatoxin Conjugate
Synthesis of HDP 30.0378 conjugate Her-DSC-30.0378 [2.8]
Figure imgf000040_0001
[00117] 1.0 mg HDP 30.0378 was dissolved in 100 μΙ dry dimethylformamide (DMF). Under argon and stirring at room temperature 10.4 μΙ of a solution of dihydroxysuccinimido carbonate (DSC) in DMF (2.56 mg in 100 μΙ DMF) and 2.1 μΙ triethylamine were added at once. The reaction mixture was stirred at room temperature. After 12 h, 30 ml cold diethylether were added. The precipitate was collected and washed several times with diethylether and dried in vacuum. The remaining solid was taken up in 200 μΙ DMF = solution A. 12.0 mg Herceptin were dissolved in 4.0 ml phosphate buffered saline (PBS, pH = 7.4) = solution B. Solution A and solution B were combined. The Herceptin amanitin-linker solution was shaken at 4°C for 14 h and separated by Sephadex G-25 gelfiltration chromatography (XK-16 column; 2 ml/min). The G-25 column was pre-washed with 500 ml PBS solutions, pH = 7.4. The Her-DSC- 30.0378 conjugate fraction was detected by UV absorption. Protein concentration was determined by RotiQuant-Assay (Carl Roth; Germany). Amanitin payload of Herceptin was determined by determination of UV absorption at A = 280 nm and A = 310 nm. A toxin payload of 2.8 amanitin molecules for each Herceptin molecule was calculated. Example 3
Cytotoxicity of Her-DSC-30.0378 [2.8] on a HER2-positive tumor cell line in vitro
[00118] Cytotoxic activity of Her-DSC-30.0378 [2.8] was evaluated with the HER2- positive tumor cell line SK-OV-3 (ovar) and a chemiluminescent BrdU incorporation assay (Roche Diagnostics) in vitro. Cell viability was determined after 72 h incubation with different concentrations of Her-DSC-30.0378 [2.8] at 37°C and 5% C02 by measurement of fixed and permealized cells with an anti-BrdU-HRP antibody in a BMG Labtech Optima microplate reader. EC50 value of dose-response curve was calculated by Graphpad Prism 4.0 software. The EC50 for Her-DSC-30.0378 [2.8] with SK-OV-3 cells was 4.1x10-1 1 M. (see Figure 2).

Claims

An amatoxin conjugate of Formula I
Figure imgf000042_0001
Formula I
wherein:
R1 = H or OH;
R2 = H or OH;
R3 = NH2 or OH;
R4 = OH or OC1-6-alkyl; and
R5 = L-T; wherein L is a linker; and T is a target binding moiety.
The amatoxin conjugate of claim 1 , wherein the linker is connected to the target- binding moiety via a urea moiety.
3. The amatoxin conjugate of claim 1 or 2, wherein the target-binding moiety is connected to the linker L via an amino group present in the target-binding moiety, wherein said amino group forms part of said urea moiety.
4. The amatoxin conjugate of any one of claims 1 to 3, wherein the linker has a length of between 1 and 8 atoms, particularly between 1 and 6, more particularly between 1 and 4, and most particularly between 2 and 4 atoms.
5. The amatoxin conjugate of any one of claims 1 to 4, wherein the linker L is an alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or a heteroaralkylene group, optionally substituted.
6. The amatoxin conjugate of any one of claims 1 to 5, wherein the linker L comprises a moiety selected from one of the following moieties: a disulfide, an ether, an amine, an ester, a carboxamide, a urethane, and a urea moiety.
7. The amatoxin conjugate of any one of claims 1 to 6 wherein the target-binding moiety specifically binds to an epitope that is present on a tumour cell, particularly wherein the target-binding moiety specifically binds to an epitope of epithelial cell adhesion molecule (EpCAM).
8. The amatoxin conjugate of any one of claims 1 to 7, wherein the target-binding moiety is selected from the group consisting of:
(i) antibody or antigen-binding fragment thereof;
(ii) antibody-like protein; and
(iii) nucleic acid aptamer.
9. The amatoxin conjugate of claim 8, wherein the target-binding moiety is an antibody or antigen-binding fragment thereof selected from: a diabody, a tetrabody, a nanobody, a chimeric antibody, a deimmunized antibody, a humanized antibody and a human antibody.
10. The amatoxin conjugate of claim 8 or 9, wherein the antigen binding fragment is selected from the group consisting of Fab, F(ab')2, Fd, Fv, single-chain Fv, and disulfide-linked Fvs (dsFv).
1 1. The amatoxin conjugate of any one of claims 1 to 10 for use as a medicament.
12. The amatoxin conjugate of any one of claims 1 to 1 1 for use in the treatment of cancer in a patient, wherein the cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma.
13. Pharmaceutical composition comprising an amatoxin conjugate according to any one of claims 1 to 10 and further comprising one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives.
14. An amatoxin-conjugation molecule of Formula I, wherein R1 to R4 are as defined in claim 1 ; and wherein R5 = L-X; wherein L is a linker; and X is a leaving group that can be replaced by a nucleophilic group of a target-binding moiety.
15. The amatoxin-conjugation molecule of claim 14, wherein X is a leaving group that can be replaced by a primary amine.
16. The amatoxin-conjugation molecule claim 14 or 15, wherein X is selected from:
-'butyloxy, -succinimidyloxy, -l -O-succinimidyloxy-3-sulfonate (-Sulfo-NHS), -0-(4- nitrophenyloxy), -0-(3-nitrophenyloxy), -0-(2,4-dinitrophenyloxy), -0-(2,4-dichloro- 6-nitrophenyloxy), -pentafluorophenyloxy, -pentachlorophenyloxy, -0-(2,4,5- trichlorophenyloxy), -0-(3,4-dihydro-3-hydroxy-4-oxo-1 ,2,3-benzotriazine-3-yl), -0-(endo-1 -hydroxy-5-norbornene-2,3-dicarboximide-1 -yl), -1 -phthalimidoyloxy, -1-benzotriazolyloxy, -1 -(7-aza-benzotriazolyl)oxy, ), and -N-imidazolyl.
17. A method for synthesizing an amatoxin conjugate of any one of claims 1 to 12, comprising the step of reacting an amatoxin-conjugation molecule of any one of claims 14 to 16 with a target-binding moiety comprising a nucleophilic group.
18. The method of claim 17, wherein said nucleophilic group is a primary amine.
19. A method of treating cancer in a patient comprising the step of administering an amatoxin conjugate according to any one of claims 1 to 1 1 , or a pharmaceutical composition of claim 13 to said patient.
20. The method of claim 19, wherein said cancer is selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, malignant melanoma, leukemia, and malignant lymphoma,
PCT/EP2012/001072 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages WO2012119787A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AU2012224848A AU2012224848B2 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
ES12708251.9T ES2532855T3 (en) 2011-03-10 2012-03-09 Amatoxin conjugates with enhanced binding
CA2829421A CA2829421C (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
CN201280012636.7A CN103442736B (en) 2011-03-10 2012-03-09 There is the amatoxin conjugate of improvement bonding
EP12708251.9A EP2683409B1 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
SG2013068135A SG193392A1 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
KR1020137026713A KR101988005B1 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
US14/004,183 US20140294865A1 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
JP2013557012A JP6105492B2 (en) 2011-03-10 2012-03-09 Amatoxin complex with improved linkage
RU2013145314/04A RU2575854C2 (en) 2011-03-10 2012-03-09 Amatoxin conjugates with improved bonds
NZ614548A NZ614548B2 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
MX2013010286A MX344009B (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages.
BR112013023015-0A BR112013023015B1 (en) 2011-03-10 2012-03-09 AMATOXIN CONJUGATE AND ITS USE, PHARMACEUTICAL COMPOSITION AND ITS USE, AMATOXIN CONJUGATION MOLECULE, METHOD FOR THE SYNTHESIS OF AN AMATOXIN CONJUGATE
UAA201311873A UA110370C2 (en) 2011-03-10 2012-09-03 Conjugates of amatoxin with improved linkages
IL228191A IL228191A (en) 2011-03-10 2013-08-29 Amatoxin-conjugates with improved linkages
ZA2013/07526A ZA201307526B (en) 2011-03-10 2013-10-09 Amatoxin-conjugates with improved linkages
HK14105777.2A HK1192839A1 (en) 2011-03-10 2014-06-18 Amatoxin-conjugates with improved linkages
US15/728,170 US20180185509A1 (en) 2011-03-10 2017-10-09 Amatoxin-conjugates with improved linkages

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11001999.9 2011-03-10
EP11001999A EP2497499A1 (en) 2011-03-10 2011-03-10 Amatoxin-conjugates with improved linkages

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/004,183 A-371-Of-International US20140294865A1 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages
US15/728,170 Continuation US20180185509A1 (en) 2011-03-10 2017-10-09 Amatoxin-conjugates with improved linkages

Publications (1)

Publication Number Publication Date
WO2012119787A1 true WO2012119787A1 (en) 2012-09-13

Family

ID=43982224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/001072 WO2012119787A1 (en) 2011-03-10 2012-03-09 Amatoxin-conjugates with improved linkages

Country Status (16)

Country Link
US (2) US20140294865A1 (en)
EP (2) EP2497499A1 (en)
JP (1) JP6105492B2 (en)
KR (1) KR101988005B1 (en)
CN (1) CN103442736B (en)
AU (1) AU2012224848B2 (en)
BR (1) BR112013023015B1 (en)
CA (1) CA2829421C (en)
ES (1) ES2532855T3 (en)
HK (1) HK1192839A1 (en)
IL (1) IL228191A (en)
MX (1) MX344009B (en)
SG (1) SG193392A1 (en)
UA (1) UA110370C2 (en)
WO (1) WO2012119787A1 (en)
ZA (1) ZA201307526B (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655531A (en) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 Tapentadol (hydrochloride) oral solution and preparation method thereof
EP2774624A1 (en) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
JP2016500058A (en) * 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド Methods for producing compounds and conjugates
CN105377304A (en) * 2014-03-10 2016-03-02 海德堡医药有限责任公司 Amatoxin derivatives
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2016071856A1 (en) 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2016141185A1 (en) 2015-03-04 2016-09-09 Board Of Regents, The University Of Texas System Methods of treating cancer harboring hemizygous loss of tp53
WO2017046658A1 (en) * 2016-04-20 2017-03-23 Hangzhou Dac Biotech Co, Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
WO2017149077A1 (en) 2016-03-03 2017-09-08 Heidelberg Pharma Gmbh Amanitin conjugates
WO2017191579A1 (en) 2016-05-05 2017-11-09 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
WO2019030171A1 (en) 2017-08-07 2019-02-14 Heidelberg Pharma Gmbh Novel method for synthesizing amanitins
WO2019030173A1 (en) 2017-08-07 2019-02-14 Heidelberg Pharma Gmbh Novel method for synthesizing amanitins
WO2019057964A1 (en) 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh Psma-targeting amanitin conjugates
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US10899843B2 (en) 2017-10-24 2021-01-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US20210030887A1 (en) * 2017-08-18 2021-02-04 Sichuan Baili Pharmaceutical Co. Ltd. Non-natural amatoxin-type antibody conjugate
EP3782654A1 (en) 2014-09-12 2021-02-24 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
WO2022058594A1 (en) 2020-09-18 2022-03-24 Araris Biotech Ag Transglutaminase conjugation method with amino acid-based linkers
WO2022084560A1 (en) 2020-10-25 2022-04-28 Araris Biotech Ag Means and methods for producing antibody-linker conjugates
US11446388B2 (en) 2016-12-23 2022-09-20 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads
US12128110B2 (en) 2017-09-19 2024-10-29 Paul Scherrer Institut Transglutaminase conjugation method and linker

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6632118B2 (en) * 2015-09-04 2020-01-15 学校法人 岩手医科大学 Drugs that suppress tumor recurrence
CA3005683A1 (en) 2015-11-27 2017-06-01 Heidelberg Pharma Research Gmbh Derivatives of gamma-amanitin
WO2017219025A1 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
CN106265480A (en) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 Nano antibody vaginal drug delivery systems and preparation method and application
EP3735987A4 (en) * 2017-09-08 2021-12-08 Sichuan Baili Pharm Co. Ltd Amanitin antibody conjugate
KR20190043031A (en) * 2017-10-17 2019-04-25 한국화학연구원 Amatoxin derivatives and methods for their preparation
EP3740233A4 (en) * 2018-01-18 2021-11-24 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd134+ cells
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
AU2020263959A1 (en) 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
BR112021023226A2 (en) * 2019-05-23 2022-01-04 Heidelberg Pharma Res Gmbh Compound, conjugate, method for synthesizing the conjugates and pharmaceutical composition
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
EP1859811A1 (en) 2006-05-27 2007-11-28 Faulstich, Heinz, Dr. Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
WO2010115629A2 (en) 2009-04-08 2010-10-14 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
WO2010115630A1 (en) 2009-04-08 2010-10-14 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
EP1859811A1 (en) 2006-05-27 2007-11-28 Faulstich, Heinz, Dr. Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
WO2010115629A2 (en) 2009-04-08 2010-10-14 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
WO2010115630A1 (en) 2009-04-08 2010-10-14 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A MULTILINGUAL GLOSSARY OF BIOTECHNOLOGICAL TERMS: (IUPAC RECOMMENDATIONS, 1995
DAVIS; PRESTON, SCIENCE, vol. 213, 1981, pages 1385 - 1388
MORRIS; VENTON, INT. J. PEPTIDE PROTEIN RES., vol. 21, 1983, pages 419 - 430
WIELAND T; FAULSTICH H, CRC CRIT REV BIOCHEM., vol. 5, no. 3, December 1978 (1978-12-01), pages 185 - 260

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500058A (en) * 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド Methods for producing compounds and conjugates
US9982018B2 (en) 2013-03-04 2018-05-29 Heidelberg Pharma Gmbh Amatoxin derivatives
WO2014135282A1 (en) * 2013-03-04 2014-09-12 Heidelberg Pharma Gmbh Amatoxin derivatives
EP2774624A1 (en) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
AU2014224928B2 (en) * 2013-03-04 2017-10-19 Heidelberg Pharma Gmbh Amatoxin derivatives
CN103655531A (en) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 Tapentadol (hydrochloride) oral solution and preparation method thereof
CN105377304A (en) * 2014-03-10 2016-03-02 海德堡医药有限责任公司 Amatoxin derivatives
JP2016516010A (en) * 2014-03-10 2016-06-02 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Amatoxin derivatives
CN105377304B (en) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 Amanita hemolysin derivative
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3693391A1 (en) 2014-09-12 2020-08-12 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
EP3782654A1 (en) 2014-09-12 2021-02-24 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
US9938323B2 (en) 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
WO2016071856A1 (en) 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
US11479774B2 (en) 2015-03-04 2022-10-25 Board Of Regents, The University Of Texas System Methods of treating cancer harboring hemizygous loss of TP53
EP3741855A1 (en) 2015-03-04 2020-11-25 Board of Regents, The University of Texas System Methods of treating cancer harboring hemizygous loss of tp53
WO2016141185A1 (en) 2015-03-04 2016-09-09 Board Of Regents, The University Of Texas System Methods of treating cancer harboring hemizygous loss of tp53
US10563204B2 (en) 2015-03-04 2020-02-18 Board Of Regents, The University Of Texas System Methods of treating cancer harboring hemizygous loss of TP53
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
WO2017149077A1 (en) 2016-03-03 2017-09-08 Heidelberg Pharma Gmbh Amanitin conjugates
WO2017046658A1 (en) * 2016-04-20 2017-03-23 Hangzhou Dac Biotech Co, Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
US10836796B2 (en) 2016-04-20 2020-11-17 Hangzhou Dac Biotech Co., Ltd. Derivatives of amanita toxins and their conjugation to a cell binding molecule
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
US10604547B2 (en) 2016-05-05 2020-03-31 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
WO2017191579A1 (en) 2016-05-05 2017-11-09 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US11446388B2 (en) 2016-12-23 2022-09-20 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US11926631B2 (en) 2017-08-07 2024-03-12 Heidelberg Pharma Research Gmbh Method of treating cancer using amanitin derivatives
WO2019030171A1 (en) 2017-08-07 2019-02-14 Heidelberg Pharma Gmbh Novel method for synthesizing amanitins
WO2019030173A1 (en) 2017-08-07 2019-02-14 Heidelberg Pharma Gmbh Novel method for synthesizing amanitins
US11702451B2 (en) 2017-08-07 2023-07-18 Heidelberg Pharma Research Gmbh Method for synthesizing amanitins
US11420971B2 (en) 2017-08-07 2022-08-23 Heidelberg Pharma Research Gmbh Method for synthesizing amanitins
US10961277B2 (en) 2017-08-07 2021-03-30 Heidelberg Pharma Research Gmbh Method for synthesizing amanitins
US20210030887A1 (en) * 2017-08-18 2021-02-04 Sichuan Baili Pharmaceutical Co. Ltd. Non-natural amatoxin-type antibody conjugate
US12128110B2 (en) 2017-09-19 2024-10-29 Paul Scherrer Institut Transglutaminase conjugation method and linker
WO2019057964A1 (en) 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh Psma-targeting amanitin conjugates
US11572411B2 (en) 2017-10-24 2023-02-07 Magenta Therapeutics, Inc. Anti-CD117 antibodies and conjugates
US10899843B2 (en) 2017-10-24 2021-01-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US11958908B2 (en) 2017-10-24 2024-04-16 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
WO2022058594A1 (en) 2020-09-18 2022-03-24 Araris Biotech Ag Transglutaminase conjugation method with amino acid-based linkers
WO2022084560A1 (en) 2020-10-25 2022-04-28 Araris Biotech Ag Means and methods for producing antibody-linker conjugates
US12076412B2 (en) 2020-10-25 2024-09-03 Araris Biotech Ag Antibody-drug conjugates through specific linker oligopeptides
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads

Also Published As

Publication number Publication date
SG193392A1 (en) 2013-10-30
US20180185509A1 (en) 2018-07-05
JP6105492B2 (en) 2017-03-29
IL228191A (en) 2016-12-29
AU2012224848A1 (en) 2013-09-12
BR112013023015B1 (en) 2022-11-29
EP2683409A1 (en) 2014-01-15
RU2013145314A (en) 2015-04-20
KR20140059163A (en) 2014-05-15
ES2532855T3 (en) 2015-04-01
EP2497499A1 (en) 2012-09-12
CA2829421C (en) 2019-02-26
CN103442736A (en) 2013-12-11
MX2013010286A (en) 2013-12-16
HK1192839A1 (en) 2014-09-05
ZA201307526B (en) 2016-07-27
NZ614548A (en) 2015-04-24
KR101988005B1 (en) 2019-06-11
BR112013023015A8 (en) 2018-01-09
UA110370C2 (en) 2015-12-25
JP2014508767A (en) 2014-04-10
MX344009B (en) 2016-12-02
BR112013023015A2 (en) 2016-12-13
US20140294865A1 (en) 2014-10-02
CA2829421A1 (en) 2012-09-13
AU2012224848B2 (en) 2016-12-22
EP2683409B1 (en) 2014-12-17
CN103442736B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
AU2012224848B2 (en) Amatoxin-conjugates with improved linkages
EP2436398B1 (en) Amatoxin-conjugates with improved linkers
US9982018B2 (en) Amatoxin derivatives
NZ614548B2 (en) Amatoxin-conjugates with improved linkages
RU2575854C2 (en) Amatoxin conjugates with improved bonds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12708251

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2829421

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/010286

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013557012

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012224848

Country of ref document: AU

Date of ref document: 20120309

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201311873

Country of ref document: UA

Ref document number: 2012708251

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013145314

Country of ref document: RU

Kind code of ref document: A

Ref document number: 20137026713

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14004183

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013023015

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013023015

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130909